Moderna Shares Rally 13% as Hantavirus Outbreak Spurs Preclinical mRNA Efforts
Moderna shares surged 13% after a Hantavirus outbreak aboard the MV Hondius infected 10 individuals and caused three fatalities from the Andes strain. Bernstein Global Research maintained a Market-Perform rating with a $45 target, citing limited pandemic risk and preclinical mRNA collaboration stage with USAMRIID and Korea University.
1. Stock Rally and Hantavirus Outbreak
Moderna stock rose 13% over several days as the Andes strain of Hantavirus infected ten passengers and crew aboard the MV Hondius, resulting in three deaths. The highly lethal variant’s human-to-human transmission history spurred investor concern and heightened demand for potential countermeasures.
2. Bernstein Maintains Market-Perform Rating
Bernstein Global Research reiterated its Market-Perform rating on Moderna, setting a $45 price target that implies a 17% downside from the May 8 close of $54.35. Analysts emphasize limited risk of a global pandemic and expect the share rally to be temporary.
3. mRNA Platform and Research Partnerships
Moderna’s scalable messenger RNA platform enables rapid pivoting toward Hantavirus countermeasures, supported by preclinical collaborations with Korea University’s Vaccine Innovation Center and USAMRIID. Both partnerships remain in early-stage research without any candidate having entered human trials.
4. Vaccine Development Costs and Funding Outlook
Developing a multi-strain Hantavirus vaccine will require Phase 1–3 trials with estimated costs exceeding $500 million. Any commercial returns are likely to come through steady government procurement and stockpiling contracts rather than mass consumer sales.